Scotia Capital Inc. Crispr Therapeutics Ag Call Options Transaction History
Scotia Capital Inc.
- $17.8 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRSP
# of Institutions
486Shares Held
58.1MCall Options Held
1.12MPut Options Held
1.73M-
Capital International Investors Los Angeles, CA7.93MShares$371 Million0.07% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$351 Million3.35% of portfolio
-
State Street Corp Boston, MA2.99MShares$140 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.97MShares$139 Million0.1% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$139 Million1.61% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.65B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....